AIMS: To determine the effect of offering smokers who want to quit easy access to nicotine replacement therapy (NRT), a period of familiarization and choice of product on smoking abstinence at 6 months. DESIGN: Single-blind, randomized controlled trial. SETTING: New Zealand. PARTICIPANTS: A total of 1410 adult smokers who called the national Quitline for quitting support were randomized to usual Quitline care or a box containing different NRT products (patch, gum, inhaler, sublingual tablet, oral pouch) to try for a week prior to quitting, and then to choose one or two of these products for 8 weeks' use. MEASUREMENTS: The primary outcome was 7-day point prevalence smoking abstinence 6 months after quit day. Secondary outcomes included continuous abstinence, cigarette consumption, withdrawal, NRT choice and serious adverse events at 1 and 3 weeks and 3 and 6 months. FINDINGS: No differences in 6-month quit rates (7-day point prevalence or continuous abstinence) were observed between the groups. However, smokers allocated to the intervention group were more likely to have quit smoking at 3 months [self-reported point prevalence, relative risk (RR)=1.17, 95% confidence interval (CI): 1.02, 1.35, P=0.03], had a longer time to relapse (median 70 days versus 28 days, P<0.01) and used significantly more NRT. The selection box concept was highly acceptable to users, with the patch and inhaler combination the most popular choice (34%). CONCLUSIONS: In terms of smoking abstinence at 6 months, offering smokers who want to quit free access to a wide range of nicotine replacement therapy, including a 1-week period of familiarization and choice of up to two products, appears no different to offering reduced cost and choice of nicotine replacement therapy, with no familiarization period. This trial is registered with the Australasian Clinical Trials Network Number: ACTRN 12606000451505.
RCT Entities:
AIMS: To determine the effect of offering smokers who want to quit easy access to nicotine replacement therapy (NRT), a period of familiarization and choice of product on smoking abstinence at 6 months. DESIGN: Single-blind, randomized controlled trial. SETTING: New Zealand. PARTICIPANTS: A total of 1410 adult smokers who called the national Quitline for quitting support were randomized to usual Quitline care or a box containing different NRT products (patch, gum, inhaler, sublingual tablet, oral pouch) to try for a week prior to quitting, and then to choose one or two of these products for 8 weeks' use. MEASUREMENTS: The primary outcome was 7-day point prevalence smoking abstinence 6 months after quit day. Secondary outcomes included continuous abstinence, cigarette consumption, withdrawal, NRT choice and serious adverse events at 1 and 3 weeks and 3 and 6 months. FINDINGS: No differences in 6-month quit rates (7-day point prevalence or continuous abstinence) were observed between the groups. However, smokers allocated to the intervention group were more likely to have quit smoking at 3 months [self-reported point prevalence, relative risk (RR)=1.17, 95% confidence interval (CI): 1.02, 1.35, P=0.03], had a longer time to relapse (median 70 days versus 28 days, P<0.01) and used significantly more NRT. The selection box concept was highly acceptable to users, with the patch and inhaler combination the most popular choice (34%). CONCLUSIONS: In terms of smoking abstinence at 6 months, offering smokers who want to quit free access to a wide range of nicotine replacement therapy, including a 1-week period of familiarization and choice of up to two products, appears no different to offering reduced cost and choice of nicotine replacement therapy, with no familiarization period. This trial is registered with the Australasian Clinical Trials Network Number: ACTRN 12606000451505.
Authors: Stevens S Smith; Paula A Keller; Kate H Kobinsky; Timothy B Baker; David L Fraser; Terry Bush; Brooke Magnusson; Susan M Zbikowski; Timothy A McAfee; Michael C Fiore Journal: Nicotine Tob Res Date: 2012-09-19 Impact factor: 4.244
Authors: Matthew J Carpenter; John R Hughes; Kevin M Gray; Amy E Wahlquist; Michael E Saladin; Anthony J Alberg Journal: Arch Intern Med Date: 2011-11-28
Authors: Ross Thomson; Sue Cooper; John Waldron; Efe Mamuzo; Lisa McDaid; Joanne Emery; Lucy Phillips; Felix Naughton; Tim Coleman Journal: Int J Environ Res Public Health Date: 2022-01-31 Impact factor: 3.390
Authors: Chris Bullen; Jonathan Williman; Colin Howe; Murray Laugesen; Hayden McRobbie; Varsha Parag; Natalie Walker Journal: BMC Public Health Date: 2013-03-08 Impact factor: 3.295